Why Did Warren Buffett Buy Amazon Stock?
When investors think of tech stocks in Warren Buffett’s portfolio,…
Sell
34
PLX Quote, Financials, Valuation and Earnings
Last price:
$1.36
Seasonality move
:
3.04%
Day range:
$1.32 - $1.40
52-week range:
$0.82 - $3.10
Dividend yield:
0%
P/E ratio:
35.00x
P/S ratio:
1.96x
P/B ratio:
2.47x
Volume:
783.5K
Avg. volume:
1M
1-year change:
19.66%
Market cap:
$111.4M
Revenue:
$53.4M
EPS (TTM):
$0.04
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target UpsideNo price target exists because of limited analyst coverage.
-
Price Target DownsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Protalix BioTherapeutics has 900% upside to fair value with a price target of $14.00 per share.
PLX vs. S&P 500
-
Over the past 5 trading days, Protalix BioTherapeutics has underperformed the S&P 500 by -8.95% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Protalix BioTherapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Protalix BioTherapeutics has grown year-over-year revenues for 3 quarters straight. In the most recent quarter Protalix BioTherapeutics reported revenues of $10.1M.
Earnings Growth
-
Protalix BioTherapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Protalix BioTherapeutics reported earnings per share of -$0.05.
Enterprise value:
76.7M
EV / Invested capital:
1.70x
Price / LTM sales:
1.96x
EV / EBIT:
13.15x
EV / Revenue:
1.28x
PEG ratio (5yr expected):
0.12x
EV / Free cash flow:
-49.11x
Price / Operating cash flow:
19.31x
Enterprise value / EBITDA:
10.71x
Gross Profit (TTM):
$29.9M
Return On Assets:
5.01%
Net Income Margin (TTM):
6.54%
Return On Equity:
10.9%
Return On Invested Capital:
8.88%
Operating Margin:
-40.99%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $41.1M | $59.7M | $59.8M | $3.7M | $10.1M | |
| Gross Profit | $24.5M | $37.2M | $29.9M | $1.1M | $1.9M | |
| Operating Income | -$13.6M | $8.1M | $4.6M | -$4.9M | -$4.1M | |
| EBITDA | -$11.4M | $10.9M | $7.2M | -$4M | -$3.4M | |
| Diluted EPS | -$0.30 | $0.01 | $0.04 | -$0.06 | -$0.05 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $90.7M | $56.5M | $55.4M | $75.4M | $60.5M | |
| Total Assets | $102.8M | $68.4M | $66.6M | $89.8M | $73.9M | |
| Current Liabilities | $80.9M | $35.3M | $31.5M | $54.8M | $24.3M | |
| Total Liabilities | $88.3M | $75.9M | $65.6M | $60M | $28.7M | |
| Total Equity | $14.5M | -$7.5M | $1M | $29.8M | $45.2M | |
| Total Debt | $55.4M | $28M | $28.3M | $20.4M | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$22.2M | $5.9M | -$572K | $4.2M | -$5.1M | |
| Cash From Investing | $16M | -$22M | $4.5M | -$606K | -$312K | |
| Cash From Financing | $22.5M | $10.4M | -$11.7M | -- | $5.1M | |
| Free Cash Flow | -$22.8M | $4.4M | -$1.6M | $3.6M | -$5.4M | |
PLX
Sector
Market Cap
$111.4M
$32.8M
Price % of 52-Week High
45.16%
46.28%
Dividend Yield
0%
0%
Shareholder Yield
-1.22%
-0.74%
1-Year Price Total Return
19.66%
-35.38%
Beta (5-Year)
-0.210
0.632
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$1.47
200-day SMA
Sell
Level
$1.85
Bollinger Bands (100)
Sell
Level
0 - 0
Chaikin Money Flow
Sell
Level
--
20-day SMA
Sell
Level
$1.55
Relative Strength Index (RSI14)
Sell
Level
28.42
ADX Line
Neutral
Level
0
Williams %R
Buy
Level
-80.9524
50-day SMA
Sell
Level
$2.07
MACD (12, 26)
Sell
Level
-0.17
25-day Aroon Oscillator
Sell
Level
-80
On Balance Volume
Neutral
Level
--
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-2.8581)
Buy
CA Score
(Annual)
Level (0.0359)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (1.0905)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (7)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.
Stock Forecast FAQ
In the current month, PLX has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The PLX average analyst price target in the past 3 months is $14.00.
-
Where Will Protalix BioTherapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Protalix BioTherapeutics share price will rise to $14.00 per share over the next 12 months.
-
What Do Analysts Say About Protalix BioTherapeutics?
Analysts are divided on their view about Protalix BioTherapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Protalix BioTherapeutics is a Sell and believe this share price will drop from its current level to $13.00.
-
What Is Protalix BioTherapeutics's Price Target?
The price target for Protalix BioTherapeutics over the next 1-year time period is forecast to be $14.00 according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is PLX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Protalix BioTherapeutics is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of PLX?
You can purchase shares of Protalix BioTherapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Protalix BioTherapeutics shares.
-
What Is The Protalix BioTherapeutics Share Price Today?
Protalix BioTherapeutics was last trading at $1.36 per share. This represents the most recent stock quote for Protalix BioTherapeutics. Yesterday, Protalix BioTherapeutics closed at $1.40 per share.
-
How To Buy Protalix BioTherapeutics Stock Online?
In order to purchase Protalix BioTherapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will RocketLab Stock Be In 5 Years?
Rocket Lab (NASDAQ: RKLB) closed recently at around $30 per share,…
Is MO dividend Worth It?
Altria Group (NYSE: MO) is paying investors $1.02 a share…
Stock Ideas
Buy
64
Is MSFT Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 40x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 49x
Sell
45
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Buy
83
GMS alert for Jun 24
GMS [GMS] is up 0.03% over the past day.
Buy
54
SMLR alert for Jun 23
Semler Scientific [SMLR] is up 16.13% over the past day.
Buy
57
GXO alert for Jun 24
GXO Logistics [GXO] is up 2.42% over the past day.
